SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals’ US arm launches Clindamycin Phosphate Foam, 1%

12 Feb 2025 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA has launched Clindamycin Phosphate Foam, 1%. Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma. Share Price

2180.65 -8.90 (-0.41%)
23-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1867.80
Dr. Reddys Labs. 1301.30
Cipla 1433.10
Zydus Lifesciences 1112.10
Lupin 2356.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: